Geçmişten Günümüze BCG Aşısı
References
Lange C, Aaby P, Behr MA, ve ark. 100 years of Mycobacterium bovis bacille Calmette-Guérin. The Lancet Infectious Diseases. 2022;22(1):e2-e12.
Ahmed A, Rakshit S, Adiga V, ve ark. A century of BCG: Impact on tuberculosis control and beyond. Immunological Reviews. 2021;301(1):98-121.
Fatima S, Kumari A, Das G, ve ark. Tuberculosis vaccine: A journey from BCG to present. Life Sciences. 2020;252:117594.
Starshinova A, Kudryavtsev I, Rubinstein A, ve ark. BCG vaccination: historical role, modern applications, and future perspectives in tuberculosis and beyond. Frontiers in Pediatrics. 2025;13:1603732.
Martinez L, Cords O, Liu Q, ve ark. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. The Lancet Global Health. 2022;10(9):e1307-e1316.
Chen J, Gao L, Wu X, ve ark. BCG-induced trained immunity: history, mechanisms and potential applications. Journal of Translational Medicine. 2023;21(1):106.
Moorlag SJCFM, Arts RJW, van Crevel R, ve ark. Non-specific effects of BCG vaccine on viral infections. Clinical Microbiology and Infection. 2019;25(12):1473-1478.
Mukherjee N, Julián E, Torrelles JB, ve ark. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond. Vaccine. 2021;39(50):7332-7340.
Lobo N, Brooks NA, Zlotta AR, ve ark. 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nature Reviews Urology. 2021;18(10):611-622.
Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nature Reviews Urology. 2018;15(10):615-625.
Aslan G, Alkaya D. Yüz Yıllık Tüberküloz Aşısı: Bacille Calmette-Guérin Tarihçesi - BCG Aşısı Koruyucu Eğitilmiş Bağışıklığı Başlatabilir Mi? Turk J Immunol. 2022;10(1):12-21.
Tagliabue A, Boraschi D, Leite LCC, ve ark. 100 Years of BCG Immunization: Past, Present, and Future. Vaccines. 2022;10(10):1743.
Bukula L, Chengalroyen MD, Omollo C, ve ark. Factors influencing the efficacy of Bacille Calmette-Guérin (BCG) vaccine. The Microbe. 2025;6:100230.
Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomedicine & Pharmacotherapy. 2007;61(6):299-305.
Cardillo F, Bonfim M, Sousa PSV, ve ark. Bacillus Calmette-Guérin Immunotherapy for Cancer. Vaccines. 2021;9(5):439.
Grier AL, Zhong JY, Basourakos S, ve ark. Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer. Cancers. 2026;18(4):623.
Unsworth-White S, Kitchen M, Bryan R. Immunotherapy for non-muscle invasive bladder cancer: from the origins of BCG to novel therapies. Future Oncology. 2022;18(1):105-115.
Greenblatt CL, Lathe R. Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors. Journal of Alzheimer’s Disease. 2024;98(2):343-360.
Zhuang L, Ye Z, Li L, ve ark. Next-Generation TB Vaccines: Progress, Challenges, and Prospects. Vaccines. 2023;11(8):1304.
Zeng S, Xing S, Zhang Y, ve ark. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment. Journal of Zhejiang University-SCIENCE B. 2024;25(7):557-567.
Mouhoub E, Domenech P, Ndao M, ve ark. The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview. Frontiers in Microbiology. 2021;12:757858.